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AbsTrACT
background lung cancer 5-year survival has doubled 
over 15 years. although the risk of second primary 
cancer is recognised, quantification over time is lacking. 
We describe the incidence of second and higher order 
smoking-related primary cancers in lung cancer survivors, 
identifying high-incidence groups and how incidence 
changes over time from first diagnosis.
Methods Data on smoking-related primary cancers 
(lung, laryngeal, head and neck, oesophageal squamous 
cell carcinoma and bladder) diagnosed in england 
between 2000 and 2014 were obtained from Public 
Health england national cancer registration and 
analysis Service. We calculated absolute incidence rates 
and standardised incidence rate ratios, both overall and 
for various subgroups of second primary cancer for up to 
10 years from the initial diagnosis of lung cancer, using 
Poisson regression.
results elevated incidence of smoking-related second 
primary cancer persists for at least 10 years from first 
lung cancer diagnosis with those aged 50 and 79 at first 
diagnosis at particularly high risk. the most frequent 
type of second malignancy was lung cancer although 
the highest standardised incidence rate ratios were 
for oesophageal squamous cell carcinoma (2.4) and 
laryngeal cancers (2.8) and consistently higher in women 
than in men. Over the last decade, the incidence of 
second primary lung cancer has doubled.
Conclusion lung cancer survivors have increased the 
incidence of subsequent lung, laryngeal, head and neck 
and oesophageal squamous cell carcinoma for at least a 
decade from the first diagnosis. consideration should be 
given to increasing routine follow-up from 5 years to 10 
years for those at highest risk, alongside surveillance for 
other smoking-related cancers.
InTroduCTIon
Five-year survival of patients with lung cancer 
has doubled in England during the past 15 years 
leading to increasing numbers of survivors.1 2 Lung 
cancer survivors are thought to be at an increased 
risk of second primary cancer (SPC).3–6 However, 
neither the way in which incidence of subsequent 
malignancy changes during follow-up nor patient 
characteristics associated with increased risk of SPC 
are well understood. We have estimated the inci-
dence of smoking-related second and higher order 
primary cancers following a primary diagnosis of 
lung cancer to determine which groups are at higher 
risk and evaluate how incidence changes over time 
following diagnosis. We have focused on cancers of 
the lung, larynx, head and neck, oesophagus (squa-
mous cell carcinoma) and urinary bladder as these 
cancers have the largest proportion of deaths attrib-
utable to cigarette smoking.7 We assessed the inci-
dence of developing an SPC at different time points 
after initial diagnosis to inform clinicians about 
optimal follow-up periods and surveillance regi-
mens after lung cancer treatment with curative 
intent.
MeThods
smoking-related primary cancers
Data from the National Cancer Registration and 
Analysis Service of Public Health England (the 
organisation responsible for cancer registration in 
England) provided information on first, second 
and higher order smoking-related primary cancers 
diagnosed in English residents aged 30–99 between 
1 January 2000 and 31 December 2014. This 
included all diagnoses of the lung (ICD-10, C33–
C34), bladder (C67), oesophageal squamous cell 
Key messages
What is the key question?
 ► What are the age and sex-specific absolute and 
relative risks of developing smoking-related 
second and higher order primary cancers 
following lung cancer?
What is the bottom line?
 ► Our population-based approach shows that 
lung cancer survivors, particularly women, have 
increased the incidence of smoking-related 
primary cancers for at least a decade from the 
time of their first primary lung cancer diagnosis, 
with those aged 50–79 at first diagnosis at 
particularly high risk.
Why read on?
 ► With improving lung cancer survival rates 
consideration should be given to extending 
lung cancer follow-up from 5 years to 10 years 
and to undertaking surveillance for other 
smoking-related cancers including head and 
neck, laryngeal and oesophageal squamous 
cell carcinoma.
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carcinoma (OSCC) (C15, morphology codes 8070–8074, 8094, 
8123, 8560), laryngeal (C32) and head and neck cancers (C00–
C14, C31). The cancer registry captures at least 98% of primary 
cancer diagnoses in England8 and records multiple primary 
cancers following International Agency for Research on Cancer 
and European Network of Cancer Registries’ rules.9 Cases clas-
sified as recurrence of first primary lung cancer were excluded. 
Data were available on tumour type (site, morphology), month 
of diagnosis as well as patient information including age at diag-
nosis, sex, income deprivation quintile and vital status (whether 
a patient was alive, dead or lost to follow-up).10 Lung cancers 
were divided into small cell lung cancer (SCLC) and non-SCLC 
(NSCLC), and NSCLC was split into adenocarcinoma, squa-
mous cell carcinoma, other NSCLC, carcinoid and unspecified 
lung (online supplementary appendix 1 table 1).
estimating expected incidence of smoking-related primary 
cancers
To evaluate whether lung cancer survivors were at an increased 
risk of SPC compared with those with no diagnosis of lung 
cancer, we estimated the number of cancers we would expect in 
people without lung cancer (online supplementary appendix 2 
figure 2). We obtained midyear population estimates for England 
from 2000 to 2014 from the Office for National Statistics and 
matched these with first primary cancers in our dataset to calcu-
late the expected age-sex-year-specific incidence rates.11 We 
matched these rates with person-years of follow-up in the cancer 
registry dataset stratified by sex, attained age and attained year. 
We multiplied the person-years of follow-up by the expected 
age-sex-year-specific incidence rates to calculate the number of 
expected cancers. We compared the number of observed and 
expected cancers to calculate standardised incidence rate ratios 
(SIRs).
statistical analysis
Analysis cohort
After restriction (online supplementary appendix 2 figure 1), 
the analysis cohort included 490 328 patients with first primary 
lung cancer. Most patients (489 740, 99.9%) had complete 
survival follow-up to death or censoring at 31 December 2014. 
Follow-up for the remaining 588 patients was censored on the 
day they were last known to be alive.
Our analyses exclude primary cancers diagnosed within 
6 months of the first primary cancer as such tumours were 
deemed likely to represent ‘synchronous’ diagnoses.
Descriptive analysis
We described absolute incidence rates and SIRs for the cohort 
from 6 months to 10 years follow-up, including by sex, age at 
diagnosis and deprivation group, as well as by the site of the 
SPC. We provide a brief summary of the incidence of subsequent 
smoking-related SPC up to 10 years from diagnosis for those 
diagnosed in 2000–2004, with complete follow-up, as other 
descriptive results may be affected by variable follow-up periods.
The choice to limit at 10 years follow-up was informed by the 
results of Kaplan-Meier survival analyses, presented in online 
supplementary appendix 4 figure 1.
Describing how risk changes over follow-up
We investigated how absolute incidence rates (second and higher 
order primary cancers diagnosed per 100 000 patient-years) and 
SIRs changed during follow-up. We plotted age-sex-specific inci-
dence rate and SIR against months of follow-up and modelled 
how the incidence rate or SIR changed over time using Poisson 
models with patient-years (incidence rate) or expected cancers 
(SIR) as exposure. We modelled elapsed follow-up time using 
restricted cubic splines allowing us to avoid the disadvantages of 
categorisation while providing for potentially non-linear associ-
ations between elapsed follow-up and SPC risk.12 13 Exploratory 
modelling guided the choice and number of knots and the inter-
action terms used in the model. The final models included pair-
wise interactions between age and follow-up, sex and follow-up, 
and age and sex, and parameterised follow-up using splines with 
knots at 6, 12, 60 and 120 months. Further interaction terms 
were not included as they decreased model fit measured using 
the Akaike information criterion.14 We used the same approach 
to evaluate changes in SIR over follow-up by the site of SPC and 
by the morphology of first primary lung cancer, removing age 
at diagnosis and sex from the model. Results were not sensitive 
to the exact knot locations (online supplementary appendix 3 
figure 1).
Describing how risk changes by year of first primary lung cancer 
diagnosis
We extended our initial approach to evaluate how the risk of 
SPC changed during different study periods, limiting observa-
tions to 6–60 months of follow-up. Based on exploratory anal-
yses, we split SPC into second primary lung cancers and other 
smoking-related primary cancers. We initially described the 
observed changes in absolute risk of second primary lung and 
other smoking-related primary cancers in patients diagnosed 
with first primary lung cancer in 2005–2009 and 2010–2014 
compared with 2000–2004. We then used the Akaike informa-
tion criterion to select an adjusted model,14 considering patient 
age, sex, deprivation and elapsed follow-up (modelled as above 
using restricted cubic splines with knots at 6, 12 and 60 months 
follow-up) and all two-way interactions. This provided a check 
that apparent differences were not explained by changes in 
patient casemix or improvements in survival.
resuLTs
description of analysis cohort
Between 2000 and 2014, 490 328 patients were diagnosed with 
first primary lung cancer (table 1). We have a priori focused on 
the 213 245 patients (43%) surviving 6 months after diagnosis, 
contributing 335 436 patient-years of follow-up (table 1; online 
supplementary appendix 4 figure 1). The median follow-up 
was 10 months per patient (IQR 4–28 months). Despite low 
survival rates, 4710 patients diagnosed in 2004 or before were 
still alive at 10 years follow-up (table 1). Survival rates were 
higher for women than men and for younger than older patients 
(online supplementary appendix 4 figure 1). Lung cancer was 
more common in patients from more deprived areas and more 
deprived patients had worse survival.
Around 1.1% (2328 of 213 245) of patients alive at 6 months 
had SPCs during follow-up, some of whom had higher order (ie, 
third or fourth) primary cancers as well. Restricting to patients 
diagnosed in 2000–2004 who survived to 6 months and have 10 
years complete follow-up gives similar results.
overall incidence of second and higher order primary cancers
Over the entire length of follow-up, SIRs for second and higher 
order primary cancer were highest for those aged 30–49 (SIR 3.4, 
95% CI 2.6 to 4.4) or 50–59 at diagnosis (SIR 2.7, 2.5 to 3.1), for 
women (SIR 2.0, 1.9 to 2.1) and for the most deprived patients 
(SIR 1.8, 1.7 to 2.0) (table 2). Patients whose first primary lung 
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Table 2 Observed and expected second and higher order primary cancers over the entire 335 436 patient-years of follow-up from 6 months after 
diagnosis to 10 years follow-up or the 31 December 2014, overall, by subsite of first primary lung cancer and by patient characteristics. Italics 
denotes the lung sub-sites
observed 
sPCs
expected 
sPCs
Absolute incidence rate per 
100 000 person-years standardised incidence rate ratio
estimate (95% CI) estimate (95% CI)
Overall 2313 1491.9 689.6 (661.7 to 718.2) 1.55 (1.49 to 1.61)
Subsite of first primary 
lung cancer
Small cell carcinoma 131 109.0 455.3 (380.7 to 540.2) 1.20 (1.00 to 1.43)
Adenocarcinoma 759 407.0 752.4 (699.8 to 807.9) 1.86 (1.73 to 2.00)
Squamous cell carcinoma (SCC) 873 497.9 882.8 (825.2 to 943.3) 1.75 (1.64 to 1.87)
Other NSCLC 312 223.0 619.4 (552.6 to 692.1) 1.40 (1.25 to 1.56)
Carcinoid 31 41.7 219.4 (149.1 to 311.4) 0.74 (0.51 to 1.06)
Unspecified lung 207 213.2 488.3 (424.0 to 559.5) 0.97 (0.84 to 1.11)
Site of SPC Lung 1460 993.8 435.3 (413.2 to 458.2) 1.47 (1.39 to 1.55)
  Small cell carcinoma 142 94.3 42.3 (35.7 to 49.9) 1.51 (1.27 to 1.78)
  NSCLC 1318 899.5 392.9 (372.0 to 414.7) 1.47 (1.39 to 1.55)
   Adenocarcinoma 485 187.8 144.6 (132.0 to 158.0) 2.58 (2.36 to 2.82)
   Squamous cell carcinoma 400 190.9 119.2 (107.8 to 131.5) 2.10 (1.90 to 2.31)
   Other NSCLC 216 143.5 64.4 (56.1 to 73.6) 1.51 (1.31 to 1.72)
   Carcinoid 13 4.4 3.9 (2.1 to 6.6) 2.98 (1.59 to 5.10)
   Unspecified lung 204 372.9 60.8 (52.8 to 69.8) 0.55 (0.47 to 0.63)
Bladder 397 299.9 118.4 (107.0 to 130.6) 1.32 (1.20 to 1.46)
Oesophageal SCC 124 52.1 37.0 (30.7 to 44.1) 2.38 (1.98 to 2.84)
Laryngeal 122 43.5 36.4 (30.2 to 43.4) 2.81 (2.33 to 3.35)
Head and neck 210 102.6 62.6 (54.4 to 71.7) 2.05 (1.78 to 2.34)
Age at diagnosis 30–49 59 17.5 316.1 (240.6 to 407.8) 3.38 (2.57 to 4.35)
50–59 332 121.0 608.3 (544.6 to 677.3) 2.74 (2.46 to 3.05)
60–69 862 428.0 779.0 (727.8 to 832.7) 2.01 (1.88 to 2.15)
70–79 833 658.9 751.4 (701.2 to 804.2) 1.26 (1.18 to 1.35)
80–99 227 266.4 558.1 (487.9 to 635.6) 0.85 (0.74 to 0.97)
Sex Male 1398 1030.7 792.7 (751.7 to 835.4) 1.36 (1.29 to 1.43)
Female 915 461.1 575.2 (538.5 to 613.7) 1.98 (1.86 to 2.12)
Deprivation quintile 1-least deprived 315 234.4 616.1 (549.9 to 688.0) 1.34 (1.20 to 1.50)
2 391 273.5 653.7 (590.5 to 721.8) 1.43 (1.29 to 1.58)
3 464 303.2 688.4 (627.2 to 754.0) 1.53 (1.39 to 1.68)
4 492 325.1 663.9 (606.5 to 725.2) 1.51 (1.38 to 1.65)
5 - most deprived 651 355.6 784.5 (725.4 to 847.2) 1.83 (1.69 to 1.98)
Period of first diagnosis 2000–2004 762 535.8 633.3 (589.2 to 680.0) 1.42 (1.32 to 1.53)
2005–2009 941 575.2 724.6 (679.1 to 772.5) 1.64 (1.53 to 1.74)
2010–2014 610 380.9 715.4 (659.8 to 774.5) 1.60 (1.48 to 1.73)
Elapsed follow-up time 6–12 months 390 450.9 401.4 (362.5 to 443.3) 0.87 (0.78 to 0.96)
1–5 years 1302 804.8 698.9 (661.4 to 737.9) 1.62 (1.53 to 1.71)
5–10 years 621 236.2 1194.9 (1102.7 to 1292.6) 2.63 (2.43 to 2.84)
cancer was adenocarcinoma (SIR 1.9, 1.7 to 2.0) or squamous 
cell carcinoma (SIR 1.8, 1.6 to 1.9) were at highest risk of SPC, 
while those with carcinoid tumours were not at increased risk 
(SIR 0.7, 0.5 to 1.1) (table 2; online supplementary appendix 4 
figure 4).
The most common smoking-related second SPC in this 
cohort was NSCLC, with 1318 SPCs (table 2), primarily 
adenocarcinoma (485 SPCs) or squamous cell carcinoma 
(400 SPCs). Bladder cancers were next most common (397 
SPCs) followed by head and neck cancers (210 SPCs). 
However, there were many more laryngeal cancers (SIR 2.8, 
95% CI 2.3 to 3.4 and OSCC, SIR 2.4, 95% CI 2.0 to 2.8) 
than would be expected given incidence rates in the general 
population, although absolute numbers of these rarer cancers 
remained small (122 laryngeal and 124 OSCC). Additional 
results on risk by the site of SPC and by histological type of 
first primary lung cancer are shown in online supplementary 
appendix 4.
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Figure 1 Absolute incidence of second and higher order smoking-
related primary cancers after lung diagnosis up to 10 years follow-up, by 
sex and age group.
Figure 2 Standardised incidence rate ratios for second and higher 
order smoking-related primary cancers after lung diagnosis up to 10 
years follow-up, by sex and age group. Results for the 30–49 age group 
are imprecise due to the small number of cancers expected in this 
group.
Figure 3 Standardised incidence rate ratios for second and higher 
order smoking-related primary cancers after lung diagnosis up to 10 
years follow-up, by site of second primary cancer. SCC, squamous cell 
carcinoma.
Variation in sPC incidence rates over follow-up
Absolute incidence rate
For patients aged 50–59, 60–69 or 70–79 at first cancer diag-
nosis, absolute incidence of SPC increased sharply from 6 to 36 
months follow-up, and then increased more slowly or remained 
stable up to 10 years after first cancer (figure 1; online supple-
mentary appendix 4 table 1). For example, at 1 year after 
first primary in men aged 50–59, incidence of SPC was 373 
per 100 000 patient-years (95% CI 298 to 468), rising to 718 
(578 to 892) at 3 years and 895 (731 to 1096) at 5 years, with the 
rate at 10 years being 999 (770 to 1296). For younger patients, 
aged 30–49 at first cancer, incidence rates remained relatively 
low throughout follow-up. For those aged 80–99, small sample 
size prevents meaningful long-term examination of SPC risk. In 
contrast to incidence in the general population, absolute inci-
dence was relatively similar for men and women with NSCLC in 
most age groups (figure 1).
Standardised incidence rate ratio
Patients aged 50–59, 60–69 and 70–79 at first lung cancer diag-
nosis had a higher-than-expected incidence of smoking-related 
SPCs from 3 to at least 10 years follow-up, when compared 
with the general population without lung cancer (figure 2; 
online supplementary appendix 4 table 1). Similar to absolute 
incidence rates, SIRs increased rapidly from 6 months to 3 years 
follow-up, but then remained stable or slightly decreased as 
follow-up continued. For example, the SIR for SPC in men diag-
nosed with first primary lung cancer aged 50–59 was 1.5 (95% 
CI 1.2 to 1.8) at 1-year follow-up, increasing to 2.8 (2.3 to 3.5) 
at 3 years. From 3 years, the SIR decreased slightly but remained 
higher than the risk in the general population over the entire 
follow-up (eg, SIR 2.9 at 5 years, 2.6 at 7 years, 2.2 at 10 years, 
online supplementary appendix 4 table 1). Results for those aged 
30–49 were highly variable due to the smaller number of cancers 
than expected in this group, and similarly to the absolute results, 
meaningful estimation of long-term SPC risk was not possible 
for those aged 80–99.
Of note, women had higher SIR for smoking-related SPC 
than men, with SIR for women aged 60–69 at diagnosis being 
3.7 (95% CI 3.2 to 4.3) at 5 years follow-up compared with 2.7 
(2.4 to 3.1) for men (figure 2). Similar differences were seen in 
other age groups.
Analysis of different cancer sites revealed that they followed 
one of three patterns. SIRs for second primary NSCLC and 
SCLC followed the same pattern as the overall SIRs, beginning 
with reduced risk but increasing over time (figure 3). SIRs for 
second primary OSCC, laryngeal cancer and head and neck 
cancer were elevated across the entire period of follow-up. SIRs 
for second primary bladder cancer were similar to the general 
population at the start and end of follow-up, appearing to peak 
at around 5 years from first primary lung cancer diagnosis, with 
an SIR at 5 years of 1.8 (95% CI 1.5 to 2.2) (figure 3).
Trends in incidence by year of first primary lung cancer diagnosis
Patients with more recent first primary lung cancers had higher 
rates of second primary lung cancers. The incidence rate among 
patients first diagnosed with lung cancer in 2010–2014 was 
715 per 100 000 patient-years (95% CI 660 to 775, table 2), 
higher than among those first diagnosed in 2000–2004 (633, 
589 to 680). Given differences in elapsed follow-up, we would 
have anticipated higher incidence rates among those diagnosed 
in earlier periods. A more detailed examination, limiting to 
data between 6 months and 5 years from diagnosis, showed that 
patients with first primary lung cancer diagnosed in 2010–2014 
had double the rate of second primary lung cancers compared 
with those with first primary diagnosis in 2000–2004 (figure 4A) 
even though most patients diagnosed in 2010–2014 had not 
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Figure 4 Incidence rate ratio for incidence of second primary cancers 
between 6 and 60 months after first primary lung cancer diagnosis in 
patients diagnosed with first primary lung cancer in 2005–2009 and 
2010–2014 compared with 2000–2004, split into lung cancer, bladder 
cancer and OSCC, laryngeal, head and neck cancer. Note that most 
patients diagnosed in 2010–2014 have less than 5 years follow-up in 
our analysis dataset. OSCC,  oesophageal squamous cell carcinomas.
reached 5 years follow-up. In contrast, rates of other smoking-re-
lated SPCs remained stable between 2000 and 2014 (figure 4A). 
Adjusting for patient age, sex, deprivation and elapsed follow-up 
did not meaningfully change these results (figure 4B).
dIsCussIon
There is strong evidence that elevated incidence of second and 
higher order primary cancers prevails for at least 10 years from 
first lung cancer diagnosis for patients aged 50–59, 60–69 and 
70–79 at first cancer diagnosis. Oesophageal squamous and 
laryngeal cancers are associated with the greatest excess inci-
dence in lung cancer survivors, although the most frequent type 
of subsequent malignancy is another lung cancer. We have also 
identified that the incidence of second primary lung cancer has 
doubled between 2000–2004 and 2010–2014.
Some recent studies have reported an increased risk of SPC 
after lung cancer compared with the general population.3–6 15–18 
One large cohort study in the USA found the incidence of second 
primary lung cancer was 1% per patient-year,18 with higher SIRs 
for women and for younger patients, but did not explore changes 
in incidence over follow-up from the first primary cancer diag-
nosis. The majority of other studies had relatively small samples 
of patients with lung cancer,4 5 15 16 preventing detailed analysis 
of incidence by patient characteristics or site of SPC. Other 
work focuses on describing factors associated with higher risk 
or incidence of SPC among patients with lung cancer.19–21 These 
show that risk varies by patient demographics and behaviour 
and are similar, if not more important, than tumour factors. 
These studies are broadly in agreement with our results that 
incidence is highest in patients aged between 50 and 79 at first 
lung cancer diagnosis with relatively small differences between 
the main histological subtypes of lung cancer.19 They confirm 
that continued smoking is associated with higher risk of SPC and 
adverse outcomes,22 with smoking cessation reducing the inci-
dence of SPC among lung cancer survivors.20
Our observation that the incidence rate of SPC is lower in the 
first 2 years of follow-up may be explained by the fact that many 
tumours, which would have been diagnosed during this period, 
were diagnosed during initial investigation for lung cancer 
and were excluded from analysis because we a priori excluded 
subsequent registrations within the first 6 months from diag-
nosis of an index smoking-related cancer. The second possibility 
is that patients with an SPC diagnosed early in follow-up may 
have been mislabelled as a recurrence of the first primary cancer 
by their treating clinicians rather than as a true SPC. This is a 
particularly plausible explanation given that the risk of non-lung 
SPCs was not reduced at the beginning of follow-up.
Major strengths of our study are its large sample size and 
population-based nature including all English residents diag-
nosed with first primary lung cancer between 2000 and 2014. 
This has allowed us to estimate age-specific and sex-specific inci-
dence for several strata and given sufficient numbers of cancer 
survivors for meaningful estimation of incidence rates even 10 
years after the first lung cancer diagnosis. The flexible parame-
terisation of follow-up time avoids arbitrary categorisation (and 
associated loss of statistical power) and enables the assessment of 
variation in incidence during the time from diagnosis.
The main study limitation is the lack of information on 
smoking status before and after diagnosis, both of which are 
moderators of SPC risk.20 Additionally, we have not been able 
to investigate the impact of tumour factors, such as stage at 
diagnosis, because this information is incomplete for most study 
years. Staging information is much more complete for patients 
diagnosed from 2013 onwards, but these patients do not yet 
have any meaningful length of follow-up for analysis.
The key implication of this work is that incidence rates for 
second and higher order primary cancers continue to rise beyond 
the end of routine specialist 5-year follow-up after an initial lung 
cancer diagnosis. Given the incidence of SPC varies substantially by 
age at first diagnosis, consideration should be given to extending 
routine follow-up from 5 to 10 years, particularly for patients aged 
50–79 at first diagnosis. In addition, this evidence can be used to 
inform lung cancer survivors and their families about the level and 
nature of risk of other organ cancers; this prognostic information 
is important for patients and clinicians and may facilitate patient 
education about possible symptoms of subsequent cancers and, 
given previous evidence of associations between continued smoking 
and incidence of further primary cancers, enhance smoking cessa-
tion among lung cancer survivors.
Surveillance efforts to promote early detection of subsequent 
smoking-related primary cancers should focus equally on both 
men and women. SIRs for second and higher order primary 
cancers are much higher in female survivors than male survivors. 
This is due to absolute incidence rates of subsequent primary 
cancers being similar for both men and women, despite inci-
dence of first primary cancers being higher among men.
Survival rates, particularly for early-stage disease, are expected 
to improve further which will lead to an increasing population 
of patients alive 5, 10 or more years from their diagnosis. Our 
findings suggest a stable increase in the incidence of smoking-re-
lated cancers among lung cancer survivors, which will lead to an 
increasing number of diagnoses of SPC. The observation that the 
incidence of second primary lung cancer has doubled between 
2000–2004 and 2010–2014 indicates that this issue is becoming 
increasingly important. The reasons behind this rapid change 
require further investigation but may be related to the changes in 
incidence of multifocal adenocarcinoma, particularly in women 
and to an increasing recognition of the issue of SPCs.
The optimal follow-up schedules and investigations to manage 
this expanding pool of cancer survivors will need to be deter-
mined by guideline development groups and policy-makers. 
Patient and clinician education about risks of SPC will be 
required to promote prompt diagnosis thereby achieving the best 
possible longer term outcomes.
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